Education & Professional Experience

Elizabeth has studied at Harvard Business School in Audit, Compensation and Corporate Governance Committees between 2019 and 2020, then at NASD (FINRA) Registered Representative between 2001 and 2008, then at in Finance, Management between 1979 and 1982, then at Marshall University in Secondary Education (Mathematics and Spanish) between 1973 and 1976.

Elizabeth worked for Genevant Sciences as Chief Financial Officer & Chief Business Officer between May 2018 and Jan 2020, for Altimmune, Inc. as Chief Financial Officer and EVP Corporate Development between Apr 2015 and May 2018, for Isarna Therapeutics as Chief Financial Officer and Chief Business Officer between Apr 2014 and Apr 2015, for Cancer Genetics, Inc. as Chief Financial Officer between Jan 2011 and Mar 2014, for Tolerx, Inc. (Assets acquired by Glaxo) as Board Member and Investor between 2008 and Jul 2012, for Radius Health, Inc. as Board Member between 2008 and Aug 2011, for JP Morgan/Bear Stearns as Managing Director/General Partner between Apr 2000 and Jan 2009.

 Skills & Competences

Elizabeth has the following skills : Mergers & Acquisitions, Due Diligence, Venture Capital, Emerging Markets, Business Development, Strategic Planning, Lifesciences, Financial Modeling, Private Equity, Licensing, Corporate Development, Management, Financial Analysis, Private Placements, Start-ups, Business Strategy, Strategy, Pharmaceutical Industry, Finance, Biotechnology.